series-c-plus
Stage
1
Investors
About
Vicore Pharma is a clinical-stage biopharmaceutical company developing an oral small molecule angiotensin II type 2 receptor agonist, buloxibutid (C21), to treat pulmonary and fibrotic diseases including idiopathic pulmonary fibrosis and pulmonary arterial hypertension.
Explore Vicore Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.